The EORTC Scientific Audit Committee (SAC) gives independent advice to the EORTC Board regarding the activities, scientific output, overall priorities, and strategies of the EORTC Divisions, Groups, and Task Forces. Recommendations also include criteria such as conformity with EORTC structure and policies as well as interaction with other EORTC Groups.
The SAC evaluates the effectiveness of the research programs conducted by the Groups. The SAC provides suggestions intended to strengthen the Groups and overall functioning of the EORTC. Each research group bearing the EORTC name is reviewed every three to four years. Approximately 50% of SAC members have no EORTC involvement. Its members represent a cross-section of international opinion and expertise. Members are committed to a three-year renewable term. The choice of EORTC members or non-EORTC members is revised as appropriate to avoid a lack of continuity in SAC reviews.
Chairs: I. Tannock, Toronto (CA) until 2016
E. Eisenhauer, Kingston (CA) as of 2017
Secretary: F. Cardoso, Lisboa (PT)
K. Ang, Houston (US)
L. Cataliotti, Firenze (IT)
C. Dittrich, Vienna (AT)
D. Lacombe, Brussels, (BE)
T. Le Chevalier, Villejuif (FR)
P. Ljungman, Stockholm (SE)
F. Meunier, Brussels (BE)
J.-Y. Pierga, Paris (FR)
M. Tempero, San Francisco (US)
M. Verheij, Amsterdam (NL)
Scientific Audit Committee Report 2013-2014
In 2013 and 2014, thirteen groups were reviewed at the SAC meeting: the Gynecological Cancer, Melanoma, Pharmacology and Molecular Mechanisms, Soft Tissue and Bone Sarcoma, Children’s Leukemia, Breast Cancer, Head and Neck Cancer, Lung Cancer, Quality of Life, Infectious Diseases, and Radiation Oncology Groups as well as the Cutaneous Lymphoma and Cancer in the Elderly Task Forces. Dr. Tannock presented an executive summary of the SAC deliberations and recommendations to the EORTC Board at its meetings in June 2013 and June 2014.